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                                                   1. INTRODUCTION 
1.1 CANCER 
Cancer is a group of diseases involving abnormal cell growth with the potential to 
invade or spread to other parts of the body. These contrast with benign tumors, 
which do not spread to other parts of the body. Possible signs and symptoms include 
a lump, abnormal bleeding, prolonged cough, unexplained weight loss, and a change 
in bowel movements. While these symptoms may indicate cancer, they may have 
other causes. Over 100 types of cancers affect humans.Tobacco use is the cause of 
about 22% of cancer deaths. Another 10% are due to obesity, poor diet, lack of 
physical activity, and excessive drinking of alcohol. Other factors include certain 
infections, exposure to ionizing radiation and environmental pollutants. In 
the developing world nearly 20% of cancers are due to infections such as hepatitis 
B, hepatitis C and human papilloma virus infection. These factors act, at least partly, 
by changing the genes of a cell. Typically many genetic changes are required before 
cancer develops. Approximately 5–10% of cancers are due to inherited genetic 
defects from a person's parents. Cancer can be detected by certain signs and 
symptoms or screening tests. It is then typically further investigated by medical 
imaging and confirmed by biopsy. Many cancers can be prevented by not smoking, 
maintaining a healthy weight, not drinking too much alcohol, eating plenty of 
vegetables, fruits and whole grains, vaccination against certain infectious diseases, 
not eating too much processed and red meat, and avoiding too 
much sunlight exposure. Early detection through screening is useful 
for cervical and colorectal cancer. The benefits of screening in breast cancer are 
controversial. Cancer is often treated with some combination of radiation therapy, 
surgery, chemotherapy, and targeted therapy. Pain and symptom management are 
an important part of care. Palliative care is particularly important in people with 
advanced disease[1].  
1.1.1. Signs and Symptoms 
When cancer begins, it produces no symptoms. Signs and symptoms appear as the 
mass grows or ulcerates. The findings that result depend on the cancer's type and 
location. Few symptoms are specific. Many frequently occur in individuals who have 
other conditions. Cancer is a "great imitator". Thus, it is common for people 
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diagnosed with cancer to have been treated for other diseases, which were 
hypothesized to be causing their symptoms. People may become anxious or 
depressed post-diagnosis. The risk of suicide in people with cancer is approximately 
double. 
Local symptoms 
Local symptoms may occur due to the mass of the tumor or its ulceration. For 
example, mass effects from lung cancer can block the bronchus resulting in cough or 
pneumonia; esophageal cancer can cause narrowing of the esophagus, making it 
difficult or painful to swallow; and colorectal cancer may lead to narrowing or 
blockages in the bowel, affecting bowel habits. Masses in breasts or testicles may 
produce observable lumps. Ulceration can cause bleeding that, if it occurs in the 
lung, will lead to coughing up blood, in the bowels to anaemia or rectal bleeding, in 
the bladder to blood in the urine and in the uterus to vaginal bleeding. Although 
localized pain may occur in advanced cancer, the initial swelling is usually painless. 
Some cancers can cause a build up of fluid within the chest or abdomen. 
Systemic Symptoms  
General symptoms occur due to effects that are not related to direct or metastatic 
spread. These may include: unintentional weight loss, fever, excessive fatigue and 
changes to the skin. Hodgkin disease, leukemia and cancers of the liver or kidney 
can cause a persistent fever. Some cancers may cause specific groups of systemic 
symptoms, termed paraneoplastic syndrome. Examples include the appearance of 
myasthenia gravis in thymoma and clubbing in lung cancer[2]. 
1.1.2. Causative Factors of Cancer 
 
Figure 1.1:  Causative factors of cancer 
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I. Chemicals 
Particular substances have been linked to specific types of cancer. Tobacco 
smoking is associated with many forms of cancer, and causes 80% of lung cancer. 
Daily long-term vaping with a high voltage (5.0 V) electronic cigarette may generate 
formaldehyde-forming chemicals at a greater level than smoking, which was 
determined to be a lifetime cancer risk of approximately 5 to 15 times greater than 
smoking. Many mutagens are also carcinogens, but some carcinogens are not 
mutagens. Alcohol is an example of a chemical carcinogen that is not a mutagen. In 
Western Europe 10% of cancers in males and 3% of cancers in females are 
attributed to alcohol. Decades of research has demonstrated the link between 
tobacco use and cancer in the lung, larynx, head, neck, stomach, bladder, 
kidney, esophagus and pancreas. Tobacco smoke contains over fifty known 
carcinogens, including nitrosamines and polycyclic aromatic hydrocarbons. Tobacco 
is responsible for about one in three of all cancer deaths in the developed world, and 
about one in five worldwide[3].  
II. Diet and Exercise 
Diet, physical inactivity, and obesity are related to approximately 30–35% of cancer 
deaths. In the United States excess body weight is associated with the development 
of many types of cancer and is a factor in 14–20% of all cancer deaths. Physical 
inactivity is believed to contribute to cancer risk not only through its effect on body 
weight but also through negative effects on immune system and endocrine 
system. More than half of the effect from diet is due to over nutrition rather than from 
eating too little healthy foods. Diets that are low in vegetables, fruits and whole 
grains, and high in processed or red meats are linked with a number of cancers. A 
high-salt diet is linked to gastric cancer, aflatoxin B1, a frequent food contaminate, 
with liver cancer, and Betel nut chewing with oral cancer. This may partly explain 
differences in cancer incidence in different countries. For example,gastric cancer is 
more common in Japan due to its high-salt diet and colon cancer is more common in 
the United States. Immigrants develop the risk of their new country, often within one 
generation, suggesting a substantial link between diet and cancer[4].  
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III. Infection 
Worldwide approximately 18% of cancer deaths are related to infectious 
diseases. Viruses are the usual infectious agents that cause cancer but 
bacteria and parasites may also have an effect. A virus that can cause cancer is 
called an onco virus. These include human papilloma virus(cervical 
carcinoma), Epstein–Barr virus (B-cell lympho  proliferative disease and 
nasopharyngeal carcinoma), Kaposi's sarcoma herpes virus (Kaposi's sarcoma and 
primary effusion lymphomas), hepatitis B and hepatitis C viruses (hepato cellular 
carcinoma), and Human T-cell leukemia virus-1 (T-cell leukemias). Bacterial infection 
may also increase the risk of cancer, as seen in Helicobacter pylori-induced gastric 
carcinoma. Parasitic infections strongly associated with cancer include Schistosoma 
haematobium (squamous cell carcinoma of the bladder) and the liver 
flukes, Opisthorchis viverrini and Clonorchis sinensis(cholangiocarcinoma)[5].  
IV. Radiation 
Up to 10% of invasive cancers are related to radiation exposure, including 
both ionizing radiation and non-ionizing ultraviolet radiation. Additionally, the vast 
majority of non-invasive cancers are non-melanoma skin cancers caused by non-
ionizing ultraviolet radiation. Sources of ionizing radiation include medical imaging, 
and radon gas. Some people, such as those with nevoid basal cell carcinoma 
syndrome or retinoblastoma, are more susceptible than average to developing 
cancer from radiation exposure. Children and adolescents are twice as likely to 
develop radiation-induced leukemia as adults; radiation exposure before birth has 
ten times the effect. Ionizing radiation is not a particularly strong mutagen. 
Residential exposure to radon gas, for example, has similar cancer risks as passive 
smoking. Low-dose exposures, such as living near a nuclear power plant, are 
generally believed to have no or very little effect on cancer development. Radiation is 
a more potent source of cancer when it is combined with other cancer-causing 
agents, such as radon gas exposure plus smoking tobacco. Prolonged exposure 
to ultraviolet radiation from the sun can lead to melanoma and other skin 
malignancies. Clear evidence establishes ultraviolet radiation, especially the non-
ionizing medium wave UVB, as the cause of most non-melanoma skin cancers, 
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which are the most common forms of cancer in the world. Non-ionizing radio 
frequency radiation from mobile phones, electric power transmission, and other 
similar sources have been described as a possible carcinogen by the World Health 
Organization's International Agency for Research on Cancer[6].  
V. Hereditary Causes 
The vast majority of cancers are non-hereditary ("sporadic cancers"). Hereditary 
cancers are primarily caused by an inherited genetic defect. Less than 0.3% of the 
population are carriers of a genetic mutation which has a large effect on cancer risk 
and these cause less than 3–10% of all cancer. Some of these syndromes include: 
certain inherited mutations in the genes BRCA1 and BRCA2 with a more than 75% 
risk of breast cancer and ovarian cancer, and hereditary non polypos is colorectal 
cancer (HNPCC or Lynch syndrome) which is present in about 3% of people 
with colorectal cancer, among others[7]. 
VI. Physical Agents 
Some substances cause cancer primarily through their physical, rather than 
chemical, effects on cells. A prominent example of this is prolonged exposure 
to asbestos, naturally occurring mineral fibers which are a major cause 
of mesothelioma, which is a cancer of theserous membrane, usually the serous 
membrane surrounding the lungs. Other substances in this category, including both 
naturally occurring and synthetic asbestos-like fibers such 
aswollastonite, attapulgite, glass wool, and rock wool, are believed to have similar 
effects. Non-fibrous particulate materials that cause cancer include powdered 
metallic cobalt andnickel, and crystalline silica (quartz, cristobalite, 
and tridymite). Usually, physical carcinogens must get inside the body (such as 
through inhaling tiny pieces) and require years of exposure to develop cancer[8].  
VII. Hormones 
Some hormones play a role in the development of cancer by promoting cell 
proliferation. Insulin-like growth factors and their binding proteins play a key role in 
cancer cell proliferation, differentiation and apoptosis, suggesting possible 
involvement in carcinogenesis. Hormones are important agents in sex-related 
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cancers such as cancer of the breast, endometrium, prostate, ovary, and testis, and 
also of thyroid cancer and bone cancer. For example, the daughters of women who 
have breast cancer have significantly higher levels of 
estrogen and progesterone than the daughters of women without breast cancer. 
These higher hormone levels may explain why these women have higher risk of 
breast cancer, even in the absence of a breast-cancer gene[9].  
VIII. Others 
Excepting the rare transmissions that occur with pregnancies and only a marginal 
few organ donors, cancer is generally not a transmissible disease. The main reason 
for this is tissue graft rejection caused by MHC incompatibility. In humans and other 
vertebrates, the immune system uses MHC antigens to differentiate between "self" 
and "non-self" cells because these antigens are different from person to person. 
When non-self antigens are encountered, the immune system reacts against the 
appropriate cell. Such reactions may protect against tumor cell engraftment by 
eliminating implanted cells. In the United States, approximately 3,500 pregnant 
women have a malignancy annually, and trans placental transmission of acute 
leukemia, lymphoma, melanoma and carcinoma from mother to fetus has been 
observed. The development of donor-derived tumors from organ transplants is 
exceedingly rare. The main cause of organ transplant associated tumors seems to 
be malignant melanoma, that was undetected at the time of organ harvest. Job 
stress does not appear to be a significant factor at least in lung, colorectal, breast 
and prostate cancers[10].  
1.1.3.Classification of Cancer 
A. Carcinoma 
Cancer that begins in the skin or in tissues that line or cover internal organs likes 
Skin cancer, Lung cancer, Colon cancer, pancreatic cancer, ovarian cancer. 
Epithelial carcinoma, Squamous carcinoma and Basal cell carcinoma, Melanoma, 
Papilloma, and Adenoma.  
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B. Sarcoma 
Cancer that begins in bone, cartilage, fat, muscle, blood vessels, or other connective 
tissues or supportive tissues is also called as bone cancer. Osteo sarcoma, Synovial 
sarcoma, Lipo sarcoma, Angino sarcoma, Rhabdo sarcoma, and Fibro sarcoma. 
C. Leukemia 
Cancer that starts in blood forming tissue such as the bone marrow and causes large 
numbers of abnormal blood cells to be produced and enter the blood is also called 
as leukemia. Lymphoblastic leukemia, Myelogenous leukemia, T-cell leukemia, and 
Hairy-cell leukemia.   
D. Lymphoma and myeloma 
cancer that begins in the cells of the immune system is called as lymphoma. T-cell 
lymphoma, B-cell lymphoma, Hodgkin lymphoma, Non-Hodgkin lymphoma and 
Lympho proliferative lymphoma.    
E. Central nervous system cancers 
Cancer that begins in the tissues of the brain and spinal cord is called as brain and 
spinal cord cancer. Glioma, Meningiomas, Pituitary adenoma,Vestibular 
schwannoma, Primary CNS lymphoma, Primitive neuroectodermal cancer[11]. 
1.1.4. Difference Between Normal Cells and Cancer Cells 
A. Normal Cells 
Normal cells carry characterstics that are essential for normal body functions. These 
cells have different in shapes and sizes but are uniform depending on what type they 
are. Human cells are eukaryotic because they contain true nucleus that contains 
genetic information DNA and RNA. These genes are responsible for all cellular 
activities and functioning. Healthy cells Divide in an orderly manner to produce more 
cells only when the body needs them. They follow a life cycle which includes mitosis 
and meiosis, and cell death-apoptosis. 
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B. Cancer Cells 
There are two distinct features that cancer cells have, cell growth not regulated by 
external signals and the capacity to invade tissue and colonize distant sites. The 
uncontrolled growth of abnormal cells is a property of all neoplasm. Neoplasm can 
either be benign or malignant[12].       
 
                     Figure 1.2: Difference between normal cells and cancer cells 
                Table 1.1:  Difference between normal cells and cancer cells     
CELL 
CHARACTERISTICS NORMAL CELLS CANCER CELLS 
 
MORPHOLOGY 
 
Normal cells have uniform 
shapes and sizes. 
Cancer cells have a large 
variety of sizes and 
shapes. The nucleuses 
have irregular structure 
and have relatively small 
cytoplasm. 
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REPRODUCTION AND 
CELL DEATH 
• Cells stop dividing 
when too much of its kind 
are present. 
• These cells grow 
and divide in a controlled 
manner and follow a 
predictable life cycle. 
• Normal cells 
undergo the process of 
apoptosis – self 
destruction if they detect 
abnormalities and damage 
in their organelles. 
 
 
 
Cancer cells don’t stop  
growing resulting to 
appearance of a tumor ( a 
cluster of mutant cells)
 
    
 
COMMUNICATION 
 
Normal cells communicate 
with each other for proper 
functioning. 
 
Cancer cells do not 
communicate with each 
other 
 
 
 
ADHESION AND 
INVASION 
 
These cells have external 
membranes that allow 
them to bond with other 
cells. 
 
 
 
These cells have the 
ability to invade or spread 
to other parts of the body 
by travelling through the 
blood stream or the 
lymphatic system – 
metastasis. 
 
 
 
SPECIALIZATION 
 
Normal cells start out as 
immature cells and mature 
with certain specialized 
functions. 
 
 
Cancer cells do not 
mature, and undergo 
apoptosis. Instead these 
cells become immature 
overtime.Cancer cells are 
primitive and they don’t 
have specialized 
functions. 
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SIGNAL RECOGNITION 
 
Normal cells recognize 
signals. They know when 
there are enough new 
cells and stops dividing.
 
 
 
Cancer cells don’t 
recognize signals. Hence 
these cells erratically 
reproduce mutated cells.
 
 
   
1.1.5. Development of Cancer 
Cancerous cells develop from healthy cells in a complex process called malignant 
transformation. 
Initiation 
The initial phase in tumor advancement is start, in which an adjustment in the cell's 
genetic material takes action to wind up plainly destructive. The adjustment in the 
cell's genetic material may happen suddenly or be expedited by an operator that 
causes tumor (a cancer-causing agent). Cancer-causing agents incorporate 
numerous chemicals, tobacco, infections, radiation, and sunlight. In any case, not all 
cells are similarly vulnerable to cancer-causing agents. A genetic defect in a cell may 
make it more helpless.  Even chronic physical irritation may make a cell more 
susceptible to carcinogens. 
Promotion 
The second and last step in the improvement of malignancy is promotion. Operators 
that reason promotion, or promoters, might be substances in nature or even a few 
medications, for example, sex hormones (for instance, testosterone taken to 
enhance sex drive and vitality in more established men). Not at all like cancer-
causing agents, promoters don't cause malignancy without anyone else. Rather, 
promoters permit a cell that has experienced starts to wind up plainly malignant. 
Advancement has no impact on cells that have not experienced start. In this manner, 
a few components, frequently the blend of a powerless cell and a cancer-causing 
agent, are expected to cause disease. A few cancer-causing agents are adequately 
effective to have the capacity to cause tumor without the requirement for 
advancement. For instance, ionizing radiation (which is utilized as a part of x-beams 
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and is created in atomic power plants and nuclear bomb blasts) can cause different 
tumors, especially sarcomas, leukemia, thyroid disease, and bosom malignancy. 
Spreading 
Tumor can grow directly into surrounding tissue or spread to tissues or organs, 
adjacent or far off. Growth can spread through the lymphatic system. This kind of 
spread is run of the mill of carcinomas. For instance, bosom tumor more often than 
not spreads initially to the adjacent lymph hubs in the armpit, and just later does it 
spread too far off locales. Tumor can also spread by means of the circulatory 
system. This sort of spread is regular of sarcomas[13]. 
 
Figure 1.3: The progress of metastasis (Courtesy by Waheed Roomi et al., 
2016, Cellular Medicine & Natural Health, June 15, 2016) 
1.1.6. Cancer Treatment 
I.Chemotheraphy 
Chemotheraphy is the treatment of tumor with at least one cytotoxic hostile to 
neoplastic medications (chemotherapeutic specialists) as a major aspect of an 
institutionalized regimen. The term incorporates an assortment of medications, which 
are partitioned into general classes, for example, alkylation specialists and anti 
metabolites. Conventional chemotherapeutic specialists act by executing cells that 
separation quickly, a basic property of most growth cells. Directed treatment is a type 
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of chemotherapy that objectives particular sub-atomic contrasts amongst disease 
and ordinary cells[14]. The main focused on treatments hindered the estrogen 
receptor molecule, restraining the development of bosom tumor. Another common 
instance is the class of Bcr-Abl inhibitors, which are used to treat continual 
myelogenous leukemia (CML).Currently, centered therapies exist for breast cancer, 
multiple myeloma, lymphoma, prostate cancer, melanoma and different cancers. The 
efficacy of chemotherapy depends on the type of cancer and the stage. In 
combination with surgery, chemotherapy has proven useful in cancer types which 
include breast cancer, colorectal cancer, pancreatic cancer, estrogenic sarcoma, 
testicular cancer, ovarian cancer and positive lung cancers. Chemotherapy is healing 
for some cancers, such as some leukemia’s, ineffective in some brain tumors. and 
unnecessary in others, such as most non-melanoma pores and skin cancers. The 
effectiveness of chemotherapy is regularly constrained by way of its toxicity to other 
tissues in the body. Even when chemotherapy does no longer provide a everlasting 
cure, it may additionally be beneficial to limit signs such as ache or to limit the 
dimension of an inoperable tumor in the hope that surgical operation will end up 
feasible in the future[15]. 
II.Radiation therapy 
Radiation therapy entails the use of ionizing radiation in an strive to either remedy or 
enhance symptoms. It works via detrimental the DNA of cancerous tissue, killing it. 
To spare normal tissues (such as pores and skin or organs, which radiation ought to 
ignore via to treat the tumor), fashioned radiation beams are aimed from a couple of 
publicity angles to intersect at the tumor, imparting a lots larger dose there than in 
the surrounding, wholesome tissue. As with chemotherapy, cancers differ in their 
response to radiation therapy. Radiation remedy is used in about half of cases. The 
radiation can be both from inner sources (brachytherapy) or exterior sources[16]. The 
radiation is most usually low power x-rays for treating pores and skin cancers, while 
greater energy x-rays are used for cancers within the body. Radiation is typically 
used in addition to surgical treatment and or chemotherapy. For positive types of 
cancer, such as early head and neck cancer, it may additionally be used alone. For 
painful bone metastasis, it has been determined to be nice in about 70% of 
patients[17]. 
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III.Surgery 
Surgery is the fundamental technique of remedy for most isolated, strong cancers 
and may play a function in palliation and prolongation of survival. It is typically an 
important phase of definitive prognosis and staging of tumours, as biopsies are 
typically required. In localized cancer, surgical operation generally attempts to 
dispose of the whole mass along with, in positive cases, the lymph nodes in the 
area. For some types of cancer this is sufficient to dispose of the cancer. 
IV.Palliative-care 
Palliative care refers to cure that tries to help the affected person experience higher 
and can also be mixed with a try to treat the cancer. Palliative care includes motion 
to limit physical, emotional, spiritual and psycho-social distress. Unlike therapy that is 
aimed at immediately killing most cancers cells, the major purpose of palliative care 
is to enhance fine of life. People at all degrees of cancer cure normally acquire some 
kind of palliative care. In some cases, medical specialty expert businesses advise 
that sufferers and medical practitioner reply to cancer only with palliative care. This 
applies to sufferers who display low overall performance status, implying restrained 
potential to care for themselves received no gain from prior evidence-based 
treatments are not eligible to take part in any excellent clinical trial no robust proof 
implies that treatment would be effective.  Palliative care may also be harassed with 
hospice and therefore only indicated when human beings method stops of life.  Like 
hospice care, palliative care tries to help the affected individual cope with 
their immediately desires and to extend comfort. Unlike hospice care, palliative care 
does now not require human beings to supply up cure aimed at the cancer. 
Multiple national scientific pointers suggest early palliative care for patients whose 
cancer has produced distressing signs and symptoms and signs or who need assist 
coping with their illness. In suffers first recognized with metastatic disease, palliative 
care can also be immediately indicated. Palliative care is indicated for patients with a 
prognosis of much less than 12months of lifestyles even given aggressive 
treatment[19].              
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V.Immunotherapy 
A range of remedies using immunotherapy, stimulating or supporting the immune 
system to battle cancer, have come into use given that 1997. Approaches 
encompass antibodies, checkpoint therapy and adoptive cellophane transfer[20]. 
VI.Laser-therapy 
Laser remedy uses high-intensity mild to deal with cancer via shrinking or destroying 
tumors or precancerous growths. Lasers are most typically used to deal with 
superficial cancers that are on the floor of the body or the lining of inner organs. It is 
used to treat basal cellophane pores and skin cancer and the very early tiers of 
others like cervical, penile, vaginal, vulgar, and non-small mobile lung cancer. It 
is frequently combined with other treatments, such as surgery chemotherapy, or 
radiation therapy. Laser-induced interstitial thermotherapy (LITT), or    interstitial 
laser photocoagulation, makes use of lasers to treat some cancers the usage of    
hyperthermia, which makes use of warmth to reduce tumors with the aid of negative 
or killing most cancers cells. Laser are more particular than surgery and motive 
much less damage, pain, bleeding, swelling, and scarring. A downside is surgeons 
have to have specialized training. It may additionally be extra steeply-priced than 
different treatments[21].    
VII. Alternative Medicine 
Complementary and choice most cancers treatments are a numerous group of 
therapies, practices and products that are now not part of conventional 
medicine."Complementary medicine" refers to strategies and materials used 
alongside with traditional medicine, whilst "alternative medicine" refers to compounds 
used instead of traditional medicine. Most complementary and choice medicines for 
cancer have no longer been studied or examined using conventional methods such 
as scientific trials. Some choice remedies have been investigated and shown to be 
ineffective however nonetheless proceed to be marketed and promoted[22,23]. 
1.2.BREAST CANCER 
The breast is made up of different tissue, ranging from very fatty tissue to very dense 
tissue. Within this tissue is a network of lobes. Each lobe is made up of tiny, tube-like 
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structures called lobules that contain milk glands. Tiny ducts connect the glands, 
lobules, and lobes, carrying milk from the lobes to the nipple. The nipple is located in 
the middle of the areola, which is the darker area that surrounds the nipple. Blood 
and lymph vessels also run throughout the breast. Blood nourishes the cells. The 
lymph system drains bodily waste products. The lymph vessels connect to lymph 
nodes, the tiny, bean-shaped organs that help fight infection. Cancer begins when 
healthy cells in the breast change and grow out of control, forming a mass or sheet 
of cells called a tumor. A tumor can be cancerous or benign. A cancerous tumor is 
malignant, meaning it can grow and spread to other parts of the body. A benign 
tumor means the tumor can grow but will not spread. Breast cancer spreads when 
the cancer grows into other parts of the body or when breast cancer cells move to 
other parts of the body through the blood vessels and/or lymph vessels. This is 
called metastasis. This guide covers early-stage and locally advanced breast cancer, 
which includes stages I, II, and III. The stage of breast cancer describes where the 
cancer is located, how much the cancer has grown, and if or where it has spread. 
Although breast cancer most commonly spreads to nearby lymph nodes, it can also 
spread further through the body to areas such as the bones, lungs, liver, and brain. 
This is called metastatic or stage IV breast cancer[24]. 
Types of breast cancer 
Breast cancer can be invasive or noninvasive. Invasive breast cancer is cancer that 
spreads into surrounding tissues. Noninvasive breast cancer does not go beyond the 
milk ducts or lobules in the breast. Most breast cancers start in the ducts or lobes 
and are called ductal carcinoma or lobular carcinoma: 
Ductal carcinoma: These cancers starts in the cells lining the milk ducts and make 
up the majority of breast cancers. 
Ductal carcinoma in situ (DCIS): This is cancer that is located only in the duct. 
Invasive or infiltrating ductal carcinoma: This is cancer that has spread 
outside of the duct. 
Lobular carcinoma: This is cancer that starts in the lobules. 
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Lobular carcinoma in situ (LCIS): This cancer is located only in the lobules. LCIS is 
not considered cancer. However, LCIS is a risk factor for developing invasive breast 
cancer in both breasts. 
Signs and Symptoms 
A lump that feels like a hard knot or a thickening in the breast or under the arm. It is 
important to feel the same area in the other breast to make sure the change is not a 
part of healthy breast tissue in that area. 
• Change in the size or shape of the breast 
• Nipple discharge that occurs suddenly, is bloody, or occurs in only 1 breast 
• Physical changes, such as a nipple turned inward or a sore in the nipple area 
• Skin irritation or changes, such as puckering, dimpling, scaliness, or new 
creases 
• Warm, red, swollen breasts with or without a rash with dimpling resembling the 
skin of an orange, called “peau d'orange” 
• Pain in the breast, particularly breast pain that does not go away. Pain is not 
usually a symptom of breast cancer, but it should be reported to a doctor. 
Causes 
After puberty, a woman's breast consists of fat, connective tissue, and thousands of 
lobules, tiny glands that produce milk for breast-feeding. Tiny tubes, or ducts, carry 
the milk toward the nipple. In cancer, the body's cells multiply uncontrollably. It is the 
excessive cell growth that causes cancer. Breast cancer usually starts in the inner 
lining of milk ducts or the lobules that supply them with milk. From there, it can 
spread to other parts of the body[25]. 
Stages 
Cancer is staged according to the size of the tumor and whether it has spread to 
lymph nodes or other parts of the body. 
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There are different ways of staging breast cancer. One way is from stage 0 to 4, but 
these may be broken down into smaller stages. 
Stage 0: Known as ductal carcinoma in situ (DCIS), the cells are limited to within a 
duct and have not invaded surrounding tissues. 
Stage 1: At the beginning of this stage, the tumor is up to 2 centimeters (cm) across 
and it has not affected any lymph nodes. 
Stage 2: The tumor is 2 cm across and it has started to spread to nearby nodes. 
Stage 3: The tumor is up to 5 cm across and it may have spread to some lymph 
nodes. 
Stage 4: The cancer has spread to distant organs, especially the bones, liver, brain, 
or lungs[26]. 
 
                   
                       Figure1.4: Anatomy of the breast cancer 
1.3 ANTI CANCER PLANTS 
Medicinal plants play a significant role as therapeutic aid in health system in all over 
the world. Therefore from ancient period to modern era herbal drugs have been used 
to cure several diseases. The medicinal value of these plants lies in some chemical 
substances that produce a definite physiological action on the  human body. These 
medicinal plants constitute an important group of non wood forest products and 
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represent a vast potential source for anti cancer compounds. Approximately 80% of 
the world population uses plant as a source of medicine for health care. India has 
been one of the pioneers in the devolpment and practice of well documented  
indigenous system of medicine, particularly Ayurvedha, Siddha and Unani System, 
all these system of medicine are gaining world wide popularity. According to WHO 
essential medicine list contain 252 drugs out of which 11% is exclusively of plant 
origin. Consequently, there has been great demand for these plants but regrettably 
only a few medicinal plants are being cultivated on a commercial scale with a 
majority still being collected from the wild. Due of over exploitation of plants have 
become endangered. For survival there is a need to conserve the wild population of 
plant in the natural or in wild condition to meet the commercial needs through 
cultivation. In the present scenario herbal medicine are in evolutionary process for 
developing new medicines therefore pharmaceutical companies are involved in 
research on plant materials for their potential medicinal values as the demand for 
herbal products is growing exponentially due to its fewer side effects as compared to 
other system of medicines. According to WHO cancer is the second most frequent 
cause of death in developed countries. Many cancer patients use complementary 
and alternative medicine treatments. A wide range of knowledge regarding 
pharmacological research has considerably in improved the quality of herbal drugs in 
cancer treatment. Among several treatments Homeopathy is one of the most popular 
complementary and alternative medicine modalities for cancer patients but due to 
the lack of knowledge about its utilization, is major factor for threatening the large 
scale for cultivation of plants[27]. Some important well known phytochemical used for 
the treatment of cancer are listed below as.     
Table 1.2: List of plants having anti cancer activity[28-35] 
S.NO PLANTS NAME FAMILY ACTIVE CONSTITUENTS 
1. Actinidia chinensis Actinidiaceae Polysaccharide 
2 Aegle marmelos Rutaceae Lupeo 
3 Agapanthus africanus Agapanthaceae Isoliquiritigenin 
4 Aglalia sylvestre Meliaceae Silvesterol 
5 Ailanthus altissima Simaraubaceae Ailnthone 
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6 Allium cepa Liliaceae 
Allicin, Alliin, Diallylsulphide, 
Quarcetin, Vitamin.C and E 
7 Allium sataivum Liliaceae 
Allicin,Alliin,Diallylsulphide 
Alliinase,S-Allylcysteine, 
Di allyl trisulphide 
8 Aloe barbadensis Liliaceae 
Aloe-emodin, 
Emodin,Aloin,Acemanan 
9 Alpinia galanga willd Zingiberaceae 
Acetoxy chavicol acetate, 
Pinocembrin,Galangin 
10 Ananas comosus Bromeliaceae Ananas bromelanin 
11 Andrographis paniculata Acanthaceae Andrographolide 
12 Angelica sinensis Umbeliferae Angelica  
13 Annona species Annonaceae Acetogenins 
14 
Aphanamixis 
polystachya 
Meliaceae Amooranin 
15 Apium  graveolens Umbeliferae Apigenin 
16 Arctium lappa Compositae Arctigenin 
17 
Astragalus 
membranaceus 
Papilionaceae Swainsonine 
18 Azadirecta indica Meliaceae Liminoids,Limbolide 
19 Bauhinia variegate Cesalpiniaceae 
Cyaniding glucoside, malvidin 
peonidin glucoside and 
kaempferol 
20 Berberis vulgaris linn Berberidaceae Berberine 
21 Betula utilis Betulaceae Betulin 
22 Bleckeria vitensis Apocyanaceae Ellipticine 
23 Brucea antidysenteria Simaraubaceae Bruceantin 
24 Bursera microphylla Burseraceae Burseran 
25 Camellia sinensis Theaceae Epigallocatechin gallate 
26 
Campotheca 
Acuminate 
Nyssaceae Campothecin 
27 Catharanthus roseus Apocyanaceae 
Vinblastin,Vincristine, 
Alstonin,Ajmalicine and 
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Reserpine 
28 Centaurea montata Asteraceae Montamine 
29 Centaurea schischkinii Asteraceae Schischkinnin 
30 
Cephalotaxus 
harringtonia 
Cephalotaxaceae Homoharringtonine 
31 Chlorella pyrenoidosa Oocystaceae Lysine 
32 Cleistanthus collinus Euphorbiaceae Cleistanthin,collinusin 
33 Colchicum luteum Liliaceae Colchicine 
34 Combretum caffrum Combretaceae Combrestatins 
35 Croton lechleri Euphorbiaceae Tapsine 
36 Curcuma longa linn Zinziberaceae Tumerone,Curcumine 
37 Daphne mezereum Thymelaeaceae Mezerein 
38 Diphylleia grayi Berberidaceae Diphyllin 
39 
Dysoxylum 
binectariferum 
Meliaceae Rohitukin 
40 Echinacea angustifolia Asteraceae 
Arabinogalactan, 
Jucogalactoxyloglucans 
41 Emblica officinalis Euphorbiaceae 
Ellagic acid,Gallic 
acid,Quercetin, Emblicannins 
A and B 
42 Erythroxylum pervillei Erythroxylaceae Pervilleine 
43 Euphorbia semiperfoliata Euphorbiaceae Jatrophane 
44 Fagopyrum esculentum Polygonaceae Amygdalin,rutin 
45 Fragaria vesca linn Rosaceae Borneol,Ellagic acid 
46 Fritillaria thunbergii Liliaceae Zhebeinone 
47 Ginkgo biloba Ginkoaceae Ginkgolide-B,A,C and J 
48 Glysine max Leguminosae 
Zinc,Selenium,Vitamins(A, 
B1,B2,B12,C,D,E,K), Amino 
acid,Isoflavones,Protease 
inhibitors,Saponins and 
Phytosterol 
49 Glycyrrhiza glabra Leguminosae Glycyrrhizin 
50 Gossypium barbadensis Malvaceae Gossypol 
51 Gunnera perpensa Gunneraceae 
2-methyl-6(3-methyl 2-
butenyl)benzo 1-4 quinone 
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52 Gyrophora esculenta Umbellicariaceae 
Poly saccharides β-
glucans,α-glucans and 
Galactomannans 
53 Hypericum perforatum Clusiaceae Hypericin 
54 Indigofera tinctoria Leguminosae Indirubins 
55 Justicia procumbens Acanthaceae Justicidin A,B 
56 Lantana camara Verbbenaceae Verbascoside 
57 Larrea tridentate Zygophyllaceae Terameprocol 
58 Lentinus edodes Agaricaceae Lentinan 
59 Linium album Linaceae Podophyllotoxin 
60 Linum usitatissimum Linaceae 
Cynogenetic 
glycoside,Lignans 
61 Lonicera japonica Caprifoliaceae Luteolin 
62 Zingiber officinale Zingiberaceae 
Curcumin,GingerenoneA, 
Gingeols, 
Shogaols,Zingerone 
63 Menthe species Labiateae Monoterpene ketones 
64 Morinda citrifolia linn Rubiaceae 
Damnacanthal,Rubiiadin-
methyl  
ether,Alizarin,Morindone and 
Anthragallol-2,3-dimethyl 
ether,Damnacanthol 
65 Nigella sativa linn Ranunculaceae 
Thymoquinone, 
Dithymoquinone 
66 Ochrosia elliptica Apocynaceae 
Ellipticine and 9-methoxy 
ellipticine are 
Pyridocarbazole,Alkaloids 
67 Ocimum sanctum linn Lamiaceae Eugenol, Orientinand vicenin 
68 Oldenlandia diffusa roxb Rubiaceae Ursolic acid 
69 Panax ginseng Aralaceae Ginsenosides,Panaxosides 
70 Pestemon deustus Serophulariaceae Liriodendrin 
71 Phaleria macrocarpa Thymelaeaceae Pinoresinol,Laricinesinol 
72 Picrorrhizia kurroa Scrophulariaceae 
Picrorrhizia,Picrosides1,2,3 
and Kutkoside 
73 Podophyllum emodii Berberidaceae Ephipodophyllotoxin 
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74 Podophyllum hexandrum Berberidaceae Podophyllin,Astragalin 
75 Polygonum cuspidatum Polygonaceae Resveratrol 
76 Prunella vulgaris linn Labiatae Ursolic acid,Oleanolic acid 
77 Psoralea corylifolia linn Fabaceae 
Bavachinin,Psoralidin, 
Psoralen 
78 Pteris multifida Pteridaceae Pterokaurane 
79 Pygeum africanum Rosaceae Amygdalin 
80 Rubia cordifolia linn Rubiaceae 
Rubidianin,Rubiadin 
rosemary 
acids,Purpurine,Alizarin, 
Xanthopurpurin 
81 
Saussurea lappa C.B 
Clarke 
Compositae 
Cynaropicrin, Costunolide 
dehydrocostuslactone, 
Shikokio 
 
82 Solanum nigrum linn Solanaceae 
Solamargine,Solasonine, 
Solanin,Quercetin 
83 Taxus brevifolia Taxaceae 
Taxanes,Taxol,Cepholomann
ine 
84 Tinospora cardifolia Menispermaceae 
Berberine,Tinosporin,Giloin, 
Gilonin 
85 Viscum album Viscaceae 
Lectin,Proprionyl 
choline,Lupeol,Viscotoxin, 
Digallic acid 
86 Vitex rotundifolia Verbenaceae Korea casticin 
                                        
1.3.1. Advantages of Anti Cancer Plants 
• Good immunomodulatory. 
• They promote host resistant against infection by stimulating both specific and 
non-specific immunity. 
• Benefit of using plant derive product over synthetic medicine have increased 
the importance of medicinal plants in the healthcare. 
• Many plants show in cancer treatment by inhibiting cancer activating 
enzymes. 
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• Stimulating DNA repair mechanism. 
• Induce anti-oxidant action. 
• To promote protective enzymes production. 
• Plant derived compounds are more tolerated and non toxic to the normal 
human cells[36].   
1.3.2. Disadvantages of Anti Cancer Plants 
• The plant or plant materials are orally injected, it causes poor absorption and 
decreased bioavailability. 
1.4. PHYTOSOMES 
Phytosomes are said to be containing natural herbal formulations. Most of the Plants 
are having medicinal properties due to the presence of many active constituents 
which are mainly the secondary metabolites like flavonoids, terpinoids, tannins,  
glycosides, alkaloids etc.  The active constituents present in the plants are mostly 
hydrophilic in nature. The therapeutic efficacy of herbal extracts are quickly 
destroyed by the enzymes present in the intestinal gut. Hence, advanced researches 
are done for the specific site delivery of these plant derived products[37]. The term 
“phyto” means plant and “some” means cell like[38]. It is also called as herbosomes. 
This is an advanced methodology, where extract of the plant or the hydrophilic 
phytoconstituents are mixed with phospholipids to produce more lipid stable 
molecular complexes, thereby it enhances the absorption and bioavailability of 
phytoconstituents[39,40,41]. Phospholipids are naturally used as an aid for digestion 
and act as carriers for both fat soluble and water soluble nutrients[42,43,44]. 
Phytosomes can easily cross the cell membranes and also stratum corneum layer of 
the skin[45,46]In the last century numerous research have been performed on a lot of 
plant extracts to know their biological importance and their use in medicinal field. 
Phytosomes  have better ability to penetrate into the membrane of the cell and from 
there  it enter into the cell and finally reaching the systemic circulation[47,48]. 
1.4.1. Phytosome Technology and its Advantages 
Hydrophilic phytoconstituents has the ability to bind with phospholipids. A specified 
amount of phospholipid (phosphatidylcholine) react with the herbal extract in a non-
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polar solvent. The phospholipid (phosphatidylcholine) used in this formulation was 
obtained from soybean with both lipophilic (phosphotidyl part) and hydroplilic 
(choline) portions. The body portion has choline group which is hydrophilic and the 
tail portion has phosphotidyl group which is lipophilic in nature, thereby the 
hydrophilic group is encoded within the lipophilic group to form a stable complex, 
phytosomes are formed[49,50]. The bonds formed are chemical in nature, which in 
additional provides better stability for the drug molecule in complex with wide range 
of advantages (Table 1.3). 
Phosphatidyl choline used in this formulation has dual function, it act as a carrier for 
drug moiety with nutritional value[51,52]. 
                                              Table 1.3: advantages of phytosomes 
S.No.                   ADVANTAGES OF PHYTOSOMES[53-56] 
 
1. Hydrophilic herbal extracts absorption is enhanced and has a 
better therapeutic effect. 
2. Phytosomes deliver the drug at specific site, so low dose is 
required to produce therapeutic effect. 
3. Phytosomes are easy to develop and has more stability than 
any other herbal formulations. 
4. The carrier used in this formulation (phosphotidylcholine)has 
an advantage that it is eco-friendly with nutritional value. 
5. Drug entrapment capacity of phytosomes is high than 
compared to any other herbal formulations. 
6. No complex techniques are not required in the production of 
phytosomes and hence low cost is required for its production. 
7. Phytosomal formulations are easily penetrate through the 
layer of the skin. Hence it can use for transdermal delivery.  
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Figure 1.5(A & B): The difference between phytosome and liposome. 
 
1.4.2. Preparation of Nanophytosomes 
Though there was not enough data available throughout the phytosome research, 
authors  tried maximum to provide all inputs for the preparation of phytosomes. The 
method for  the preparation of phytosomes are as follows: In the first step, 
phospholipids are obtained  from either natural or synthetic sources are to be 
dissolved in a organic solvent such as  acetone or dioxane. To the solution of 
phospholipids, herbal extract is added with constant stirring. Then the solution is 
allowed to evaporate on a spray dryer.The ratio between the portions in the range of 
0.5 to 2.0 moles but the most preferable ratio is1:1[57,58]. Thin flim is formed after 
evaporation of the solvent. Futher hydration of the flim leads to formation of 
phytosomal suspension. The formed phytosomes will be collected by precipitation 
technique. The collected phytosomes are futher subjected to drying by lyophilisation 
method [59,60]. The entire preparations are illustrated in schematic way for better 
understanding to the users (Fig 1.6).                            
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Figure 1.6: Schematic illustration of preparation of nanophytosomes. 
1.4.3. Characterization and Evaluation of Phytosomes 
The characterization techniques for the evaluation of phytosomes are as follows  
i. Vesicle size and Zeta potential: The particle size and zeta potential can be 
determined by DLS using a computerized inspection system. 
ii. Surface morphology analysis: By using scanning electron microscopy 
(SEM) the surface morphology analysis of phytosomes can be determined. 
iii. Transition temperature: By using differential scanning calorimetry the 
transition temperature of the vesicular lipid system can be determined. 
iv. Surface tension measurement: Du novy ring densitometer is used to find 
out the surface tension activity of a drug dissolved in aqueous solution.  
v. Entrapment efficiency:  By using ultracentrifugation technique the drug 
entrapment ability of phytosomes can be measured.  
vi. Drug content:  Drug content present in the phytosomes can be determined 
by High performance liquid chromatographic method or any other 
spectroscopic methods. 
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vii. Stability studies: Stability studies were carried out for two months on the 
optimized formulation of phytosomes. For stability study the optimized 
formulation were placed in humidity chamber (sonar) at 75%RH,450c. After 
two months, the formulation was evaluated for weight variation, hardness, 
friability, disintegration and percentage drug content[61-64]. 
1.4.4. Spectroscopic Evaluations 
The spectroscopic evaluation provides more information about phytosomes. They 
are as follows: 
i)FT-IR:The FT-IR spectra data will be taken to determine the structure and chemical 
shift of the extract, phosphotidylcholine and phytosomes. 
 ii)1H-NMR: The 1H-NMRspectra is used to determine the development of complex 
formed between active phytoconstituents and phosphotidylcholine molecules. In non 
polar solvents, there will be an evident change in 1H-NMR signal commencing from 
atoms included in the complex formation. The signals from protons are broadened. 
In phospholipids there is broadening of signals whereas the singlet correlative to the 
N- trimethyl portion of choline yields an upfield shift. 
iii)13C-NMR: The 13C-NMR of phytosomes, when recorded at room temperature all 
the carbons in phytoconstituents are unobservable. The signals equivalent to the 
choline and glycerol portion was broadened, whereas some are shifted and most of 
the resonance of the fatty acids chains maintains their initial sharp lines[65,66]. 
1.4.5. Commercial Products in Market 
To date, very few products has came in to market and said to be commercially 
available. The list of available (Table 1.4) components is enlisted here for readers. 
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                Table 1.4:Marketed preparation of phytosomes  
                                
 
 
S.No. Nanophytosomes Phytoconstituents Therapeutic Applications 
1. 
 
Silybin 
Phytosome 
Silybin from 
Silybum marianum 
Hepatoprotective, 
antioxidant for liver and skin 
2. 
Ginkgo 
Phytosome 
24% ginkgo 
flavonoids  
Protects brain and vascular 
linings, anti-skin 
Ageing 
3. 
 
Ginseng 
Phytosome 
37.5% 
ginsenosides  
Nutraceuticals, 
immunomodulator 
 
4. 
Green Tea 
Phytosome 
Epigallocatechin  
Nutraceutical, systemic 
antioxidant, anticancer 
5. 
Grape Seed 
Phytosome 
Procyanidins  
Nutraceutical, systemic 
antioxidant, cardioprotective 
6. 
Hawthorn 
Phytosome 
Flavonoids  
Nutraceutical, cardio-
protective and 
antihypertensive. 
7. 
Olive oil 
Phytosome 
Polyphenols  
Antioxidant, anti-
inflammatory, 
antihyperlipidemic. 
8. 
Echinacea 
Phytosome 
Echinacosides  
Nutraceutical, 
immunomodulatory 
9. 
Centella 
Phytosome 
Terpenes Vein and Skin disorders 
10. 
Palmetto 
berries 
Phytosomes 
Fatty acids, 
alcohols and 
sterols 
Non-cancerous prostate 
enlargement 
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2. PLANT PROFILE 
 
Figure 2.1:  Momorica Charantia 
2.1. Taxonomy of Momorica Charantia 
The botanical classification of Momorica Charantia is as following,  
                                          Kingdom     : Plantae    
            Division       : Magnoliophyta    
                                          Class           : Magnoliopsida 
                                                 Order          : Cucurbitales 
                                                 Family         : Cucurbitaceae 
                                                Genus          : Momordica 
                                                 Species       : Charantia 
2.2. Vernacular Names of Momordica Charantia 
                                          English        : Bitter gourd 
                                          Tamil           : pakal/paavakka 
                                          Chinese      : kugua 
                                          Japanese   : nigauri 
                                          Okinawan   : goya 
                                          Gujarati      : karela 
                                          Marathi       : karala 
                                          Hindustani  : karavila 
                                          Malayalam  : kaipakka/paavakka 
                                          Kannada     : hagala 
                                          Telugu         : kakarakaya 
                                          Assamese   : kerela 
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2.3. Morphology 
Leaves: simple, usually palmately 5-7 lobed, tendril sun branched or 2 branched. 
The herbaceous,tendril bearing vine grows to 5 m. It bears simple, alternate leaves 
4–12 cm across, with 3–7 deeply separated lobes. 
Fruit: ovoid, ellipsoid, or spindle shaped, usually ridged or warty, dehiscent 
irregularly as a 3   valves fleshy capsule or indehiscent. The fruit has a distinct warty 
looking exterior and an oblong shape. It is hollow in cross-section, with a relatively 
thin layer of flesh surrounding a central seed cavity filled with large flat seeds and 
pith. Seeds and pith appear white in unripe fruits, ripening to red; the flesh is crunchy 
and watery in texture, similar to cucumber, chayote or green bell pepper.  
Flowers: Staminate flowers usually solitary on a bracteate scape, hypanthium 
shallow, calyx 5 lobed, petals 5,usually yellow, distinct, 1-3 with incurved scales at 
base, stamensusually 3, inserted toward base of hypanthium, filaments distinct, 
broad, anthers distinct or coherent, 2 ofthem dithecal, the other monothecal, cells 
curved or flexuous; pistillate flowers usually solitary on a bracteatescape, 
hypanthium ovoid to spindle shaped, perianthusually smaller than in staminate 
flowers, staminodesabsent or 3, ovules numerous, horizontal, stigmas 3, 2 lobed. 
Seeds few to numerous, ovate, usually sculptured[67].  
2.4. Plant Parts Used    
The Momodrica Charantia leaves are used. 
2.5. Distribution 
The original home of the species is not known, other than that it is a native of the 
tropics. Bitter melon grows in tropical areas, including parts of the Amazon, east 
Africa, Asia, and the Caribbean. It is widely grown in India and other parts of the 
Indian subcontinent, Southeast Asia, China, Africa, and the Caribbean. 
2.6. Phytochemical Constituents 
Momordica charantia has a non-nitrogenous neutral principle charantin, and on 
hydrolysis gives   glucose and asterol. The fruit pulp of momordica charantia has 
soluble pectin but no free pectic acid. Galactouronic acid is also obtained from the 
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pulp. Momordica charantia fruits glycosides, saponins, alkaloids, reducing sugars, 
resins, phenolic constituents, fixed oil and free acids. The presence of anun 
identified alkaloid and 5-hydroxytryotamine is also reported. The 5HT content is 
reported to be present. Theether extract residue of the alcoholic concentrate from 
the leaves of Momordica charantia is reported to reveal hypoglycemic activity 
comparable to that of tolbutamide. The pure protein termed as P-insulin extracted 
from momordica charantia fruits in crystalline form is also tested[68].  
2.7. Traditional Uses 
In traditional medicine of India, different parts of the plant are used as claimed 
treatments for diabetes (particularly Polypeptide-p, an insulin analogue), and as a 
stomachic, laxative, antibilious, emetic, anthelmintic agent, for the treatment of 
cough, respiratory diseases, skin diseases, wounds, ulcer, gout, and rheumatism. 
Momordica charantia has a number of purported uses including cancer prevention, 
treatment of diabetes, fever, HIV and AIDS, and infections. For cancer prevention, 
HIV and AIDS, and treatment of infections, there is preliminary laboratory research, 
but no clinical studies in humans showing a benefit. In 2017, the University of 
Peradeniya researchers revealed that bitter gourd seeds can be potentially used to 
destroy cancer cells and they were successfully administered to patients inK andy 
General Hospital Cancer Unit. The Memorial Sloan Kettering Cancer Center 
concludes that bitter melon "cannot be recommended as a replacement therapy for 
insulin or hypoglycaemic drugs"[69].    
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3. REVIEW OF LITERATURE 
1. Mamdouh Mali et al., (2017) reported in spite of the wide facilities for controlling 
cancer growth, there are little drugs to inhibit its metastasis or prevent 
its angiogenesis. Discovering such natural or synthetic multi-targeted agent that 
might strike different targets is considered as a vital goal for tumor controlling. In a 
previous study, the chemo protective effect of methanol extract of Momordica 
charantia (MEMC) on albino western rats bearing hepato carcinogenesis was 
evaluated. The mechanism by which MEMC exert its anticancer properties was 
unknown. Therefore, we aimed in this study to investigate the possible role of MEMC 
as anti-proliferative, anti-angiogenic and anti-metastatic agent to exert its chemo 
protective effect. MEMC treatment significantly decreased Cox-2, VEGF, HDAC and 
MMP-2,-9 and increased Casp-3,−8 as compared to DENA group, which 
demonstrated that the anticancer effect of MEMC may be through the inhibition of 
angiogenesis, proliferation and metastasis and the activation of apoptosis[70].  
2. Sur et al., (2017) reported head and neck squamous cell carcinoma (HNSCC) is 
the sixth most common cancer worldwide, and tobacco is one of the most common 
factors for HNSCC of the oral cavity. We have previously observed that bitter melon 
(Momordica charantia) extract (BME) exerts anti proliferative activity against several 
cancers including HNSCC. In this study, we investigated the preventive role of BME 
in 4-nitroquinoline 1-oxide (4-NQO) carcinogen-induced HNSCC. We observed that 
BME feeding significantly reduced the incidence of 4-NQO-induced oral cancer in a 
mouse model. Histologic analysis suggested control 4-NQO-treated mouse tongues 
showed neoplastic changes ranging from moderate dysplasia to invasive squamous 
cell carcinoma, whereas no significant dysplasia was observed in the BME-fed 
mouse tongues. We also examined the global transcriptome changes in normal 
versus carcinogen-induced tongue cancer tissues, and following BME feeding[71].  
3. Bhattacharya et al., (2017) reported natural killer (NK) cells are one of the major 
components of innate immunity, with the ability to mediate antitumor activity. 
Understanding the role of NK-cell-mediated tumor killing in controlling of solid tumor 
growth is still in the developmental stage. We have shown recently that bitter melon 
extract (BME) modulates the regulatory T cell (Treg) population in head and neck 
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squamous cell carcinoma (HNSCC). However, the role of BME in NK-cell modulation 
against HNSCC remains unknown. In this study, we investigated whether BME can 
enhance the NK-cell killing activity against HNSCC cells. Our results indicated that 
treatment of human NK-cell line (NK3.3) with BME enhances ability to kill HNSCC 
cells[72]. 
4. Vermont Dia et al ., (2016) reported momordica charantia is a perennial plant 
with reported health benefits. BG-4, a novel peptide from Momordica charantia, was 
isolated, purified and characterized. The trypsin inhibitory activity of BG-4 is 8.6 
times higher than purified soybean trypsin inhibitor. The high trypsin inhibitory activity 
of BG-4may be responsible for its capability to cause cytotoxicity to HCT-116 and 
HT-29 human colon cancer cells with ED50 values of 134.4 and 217.0 μg/mL after 
48 h of treatment, respectively. The molecular mechanistic explanation in the 
apoptosis inducing property of BG-4 is due to reduced expression of Bcl-2 and 
increased expression of Bax leading to increased expression of caspase-3 and 
affecting the expression of cell cycle proteins p21 and CDK2. This is the first report 
on the anti-cancer potential of a novel bioactive peptide isolated from Momordica 
charantia in vitro supporting the potential therapeutic property of BG-4 against colon 
cancer that must be addressed using in vivo models of colon carcinogenesis[73]. 
5. Mohammed Alshehri et al., (2016) reported  natural products are the best source 
for various medicinal drugs. Regardless investigate the toxic effect of these plant 
extracts, the results will still unsafe and unacceptable. This study aimed to identify 
anti-cancer activity and cytotoxicity effect of Momordica charantia extract on different 
cancer cell line. To archive the aim of this study 3 different cancer cell lines 
(HCT116, MCF-7, and HepG2) were treated with different Momordica charantia 
extract doses (from 0-100μg) for each cell line. IC50, cell viability, apoptosis, were 
evaluated. The effect  of Momordica charantia extract was highly significant in 
HepG2 cells than HCT116cell as well as MCF-7 which showing the IC50 of 
Momordica charantia extract in HepG2 was 0.77 μg/ml whilein HCT116 was 
0.81μg/ml and was 1.35μg/ml in MCF-7 cells respectively. Also, the effect of the 
Momordica charantia extract was more potent in HCT116 compared to MCF-7 
cells[74].  
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 6. Mingo Yung et al., (2015) reported Acquired chemoresistance is a major 
obstacle in the clinical management of ovarian cancer. Therefore, searching for 
alternative therapeutic modalities is urgently needed. Bitter melon (Momordica 
charantia) is a traditional dietary fruit, but its extract also shows potential medicinal 
values in human diabetes and cancers. Here, we sought to investigate the extract of 
bitter melon (BME) in antitumorigenic and cisplatin-induced cytotoxicity in ovarian 
cancer cells. Three varieties of bitter melon were used to prepare the BME. Ovarian 
cancer cell lines, human immortalized epithelial ovarian cells (HOSEs), and nude 
mice were used to evaluate the cell cytotoxicity, cisplatin resistance, and tumor 
inhibitory effect of BME. The molecular mechanism of BME was examined by 
Western blotting.  Cotreatment with BME and cisplatin markedly attenuated tumor 
growth in vitro and in vivo in a mouse xenograft model, whereas there was no 
observable toxicity in HOSEs or in nude mice in vivo[75].  
7. Shobha et al., (2015) reported to estimate the total phenol content (TPC)of the 
ethanolic extract of Momordica charantia (EEMC)whole fruit and to study the 
cytotoxic activity of this extract against cell lines representing carcinomas of cervix 
and breast. Cervical and breast carcinoma cell lines (HeLa and MCF-7) were 
procured from National Center for Cell Sciences, Pune, and cultured in Dulbecco’s 
modified eagle medium (DMEM)supplemented with 10% fetal bovine serum (FBS) 
and1 mM L-glutamine. EEMC was prepared by graded ethanol fractionation method 
and the TPC determined using Folin–Ciocalteu assay. For cytotoxicity studies,5000 
cells/well in 100 μl DMEM-10% FBS medium were seeded in a 96 well plate; and 
treated with increasing concentration of EEMC. Efficacy of EEMC was determined by 
measuring the cell number using sulforhodamine B assay[76].  
8. Gunasekar Manoharan et al., (2014) reported prior to the availability of 
chemotherapeutic agents, dietary measures, including traditional medicines derived 
from plants, were the major forms of cancer treatment. One such plant is Momordica 
charantia (Family: Cucurbitaceae), whose fruit is known as corilla or bitter 
gourd/melon. M. charantia possesses anti-carcinogenic properties and it can 
modulate its effect via xenobiotic metabolism and oxidative stress. This study 
investigated the anti-cancer effect of an active water-soluble extract (s) of M. 
charantia on cell viability and its cellular mechanism(s) of action in inducing cell 
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death. Both time course (800 µg/ml) and dose- dependent (200 µg/ml800 µg/ml) 
experiments were performed treating six different cancer cell lines, namely 1321N1, 
Gos-3, U87-MG, Sk Mel, Corl -23, Weri Rb-1 and normal L6 muscle cell line with the 
crude fruit extract for 24-48 hours at 37 °C. Cell viability was measured using the 
MTT assay[77].  
9. Sara Abozaid et al., (2014) reported Cancer today represents a significant public 
health problem worldwide and the challenge is to produce cost effective drugs. 
Recently, a surge of progress was achieved in the area of cytotoxic proteins. Eleven 
crude protein extracts, from different plants, were tested for anticancer activities 
against four cell lines; HepG2, Caco-2, HEP-2,and HeLa cells using MTT assay. Out 
of the tested extracts, Momordica charantia showed the highest anticancer potency 
of all tested protein fractions that is superior than that of 5-FU. Furthermore, its 
anticancer activity was characterised by the selective growth inhibitory effect on 
epithelial derived cell lines, HeLa, Caco-2 andHEP-2, but not in HepG2. On the other 
hand, Lactuca sativa protein fraction exhibited a potent and a selective anti cancer 
activity against HepG2 that could be used as a lead for further investigations in the 
area of liver cancer therapy. In conclusion, although these findings are very 
promising and may open an avenue towards an economic plant-based selective 
anticancer drug, the exact chemical nature of active fractions remains to be fully 
explored and elucidated[78]. 
10. Chia-Jung Li, et al., (2012) reported Plants are an invaluable source of potential 
new anti-cancer drugs. Momordica charantia is one of these plants with both edible 
and medical value and reported to exhibit anticancer activity. To explore the potential 
effectiveness of Momordica charantia, methanol extract of Momordica 
charantia (MCME) was used to evaluate the cytotoxic activity on four human cancer 
cell lines, Hone-1 nasopharyngeal carcinoma cells, AGS gastric adenocarcinoma 
cells, HCT-116 colorectal carcinoma cells, and CL1-0 lung adenocarcinoma cells, in 
this study. MCME showed cytotoxic activity towards all cancer cells tested, with the 
approximate IC50 ranging from 0.25 to 0.35 mg/mL at 24 h. MCME induced cell death 
was found to be time-dependent in these cells. Apoptosis was demonstrated by 
DAPI staining and DNA fragmentation analysis using agarose gel electrophoresis[79].  
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11. Pitchakarn et al., (2012) reported  in this study, we focused on the invitro effects 
of kuguacin J, purified component of bitter melon(momordica charantia) leaf 
extract(BMLE) on androgen- independent  human prostate cancer cell line PC3 and 
the invivo effect of dietary BMLE on prostate carcinogenesis using a PC3-xenograph 
model. Interestingly, KuJ also  dramatically decreased the level of survivin expressed 
by PC3 cells. In addition , KuJ exerted anti-invasive effects on PC3 cells. In addition 
,KuJ inhibited secretion of the active forms of MMP-2,MMP-9 and uPAby PC3 cells. 
In addition KuJ treatment significantly decreased the expression of membrane type 
1-MMP (MT1-MMP) by PC3cells. In vivo , 1% and 5% BMLE in the diet resulted in 
63% and 57% inhibition of PC3 xenograph growth without adverse effect on host 
body weight. Our results suggest that KuJ is a promising new candidate chemo 
preventive and chemotherapeutic agent for prostate cancer[80]. 
12. Peng Ru et al., (2011) reported prostate cancer remains the second leading 
cause of cancer deaths among American men. Earlier diagnosis increases survival 
rate in patients. However, treatments for advanced disease are limited to hormone 
ablation techniques and palliative care. Thus, new methods of treatment and 
prevention are necessary for inhibiting disease progression to a hormone refractory 
state. One of the approaches to control prostate cancer is prevention through diet, 
which inhibits one or more neoplastic events and reduces the cancer risk. In this 
study, we have initially used human prostate cancer cells, PC3 and LNCaP, as an in 
vitro model to assess the efficacy of bitter melon extract (BME) as an anticancer 
agent. We observed that prostate cancer cells treated with BME accumulate during 
the S phase of the cell cycle and modulate cyclin D1, cyclin E, and p21 expression. 
Treatment of prostate cancer cells with BME enhanced Bax expression and induced 
PARP cleavage[81].  
13. Pitchakarn  et al., (2011) reported  in this study, we focused on the effects of a 
bitter        melon(momordica charantia) leaf extract(BMLE) and a purified component, 
kuguacin J, on androgen dependent LNCaP human prostate cancer cells. Both 
treatments exerted    growth inhibition through G1 arrest and induction of apoptosis. 
Down –regulation of p53 by RNA interference indicated that BMLE and KuJ inhibited 
cell growth partly through p53-dependent cell cycle arrest and apoptotic pathways. 
Both BMLE and KuJ caused less toxicity in a normal prostate cell line, PNT1A. Our 
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results suggest that BMLE and a purified component, KuJ, from its diethyl ether 
fraction could be promising candidate new anti neoplastic and chromo preventive 
agents for androgen-dependent prostate cancer and carcinogenesis[82]. 
14. Wei-Hsiung Yang et al., (2011) reported adreno cortical carcinomas are rare but 
present with extremely poor prognosis. One of the approaches to control cancer 
progression and reduce cancer risk is prevention through diet. In this study, we have 
used human and mouse adreno cortical cancer cells as an in vitro model to assess 
the efficacy of bitter melon extract (BME) as an anticancer agent. The protein 
concentrations of BME and other extracts were measured before use. First, BME 
treatment of adreno cortical cancer cells resulted in a significantly dose-dependent 
decrease in cell proliferation. However, we did not observe an anti proliferative effect 
in adreno cortical cancer cells treated with extracts from blueberry, zucchini, and 
acorn squash. Second, apoptosis of adreno cortical cancer cells was accompanied 
by increased caspase-3 activation and poly(ADP-ribose) polymerase cleavage. 
Third, BME treatment decreased the key proteins involved in steroidogenesis in 
adrenocortical cancer cells[83].  
15. Ray et al., (2010) reported Breast cancer is one of the most common cancers 
among women in the United States. Although there are effective drugs for treating 
advanced stages of breast cancers, women eventually develop resistance. One of 
the approaches to control breast cancer is prevention through diet, which inhibits one 
or more neoplastic events and reduces cancer risk. In this study, we have used 
human breast cancer cells, MCF-7 and MDA-MB-231, and primary human mammary 
epithelial cells as an in vitro model to assess the efficacy of bitter melon (Momordica 
charantia) extract (BME) as an anticancer agent. BME treatment of breast cancer 
cells resulted in a significant decrease in cell proliferation and induced apoptotic cell 
death. Apoptosis of breast cancer cells was accompanied by increased poly(ADP-
ribose) polymerase cleavage and caspase activation. Together, these results show 
that BME modulates signal transduction pathways for inhibition of breast cancer cell 
growth and can be used as a dietary supplement for prevention of breast cancer[84]. 
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16. Pornsiri Pitchakarn et al., (2010) reported cancer metastasis is a major cause 
of death in cancer patients, with invasion as a first step greatly contributing to the 
failure of clinical treatments. Any compounds with an inhibitory influence on this 
process are therefore of prime interest. Momordica charantia is widely consumed as 
a vegetable and especially as a folk medicine in Asia. Here , we investigated the anti 
–invasive effects of bitter melon leaf extract (BMLE) on a rat prostate cancer cell 
line(PLS10) in vitro and in vivo. The results indicated that non-toxic concentrations of 
BMLE significantly inhibited the migration and invasion of cells in vitro. The results of 
zymography  showed that BMLE inhibited the secretion of MMP-2, MMP-9  and 
urokinase plasminogen activator from PLS10[85].  
17. Li M et al., (2009) reported ribosome-inactivating proteins (RIPs) are a family of 
enzymes that depurinate rRNA and inhibit protein biosynthesis. Here we report the 
purification, apoptosis-inducing activity, and polyethylene glycol (PEG) modification 
of RIP from the bitter melon seeds. The protein has a homogenous N-terminal 
sequence of NAsp- Val-Ser-Phe-Arg. Moreover, the RIP displayed strong apoptosis-
inducing activity and suppressed cancer cell growth. This might be attributed to the 
activation of caspases-3. To make it available for in vivo application, the 
immunogenicity of RIP was reduced by chemical modification with 20 kDa 
(mPEG)(2)-Lys-NHS. The inhibition activity of both PEGylated and non-PEGylated 
RIP against cancer cells was much stronger than against normal cells, and the 
antigenicity of PEGylated RIP was reduced significantly[86].  
18. Kobori et al., (2008) reported  bitter gourd ( Momordica charantia L.) pericarp, 
placenta, and seed extracts were previously shown to induce apoptosis in HL60 
human leukemia cells. To determine the active component that induces apoptosis in 
cancer cells, bitter gourd ethanol extract was fractionated by liquid-liquid partition 
and silica gel column chromatography. Several fractions obtained by silica gel 
column chromatography inhibited growth and induced apoptosis in HL60 cells. 
(9Z,11E,13E)-9,11,13-Octadecatrienoic acid (alpha-eleostearic acid) is known to be 
the major conjugated linolenic acid in bitter gourd seeds. Therefore, the effect of 
alpha-eleostearic acid on the growth of some cancer and normal cell lines was 
examined. alpha-Eleostearic acid strongly inhibited the growth of some cancer and 
fibroblast cell lines, including those of HL60 leukemia and HT29 colon carcinoma[87].  
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4. AIM AND OBJECTIVE 
4.1. Aim 
The aim of our study is to prepare nanophytosomes of aqueous extract of leaves of 
Momordica Charantia and to evaluate them for its in vitro anti cancer activity in a 
MDA-MBhuman breast cancer cell lines. 
4.2. Objectives 
The objectives of the present research work focused on the investigation of phyto 
chemical constituents of aqueous extract, preparation of nanophytosomes of 
aqueous extract and study of anti cancer activity in a MDA-MBhuman breast cancer 
cell lines. 
The specific objectives are as follows, 
1. Collection of Momordica  Charantia leaves. 
2. Processing of leaves to prepare aqueous extract using decoction method. 
3. Preliminary Phytochemical Investigation of aqueous extract of leaves of 
momordica charantia . 
4. Preparation of nanophytosomes of aqueous extract of momordica charantia. 
5. Characterization of Aqueous extract of Momordica Charantia 
nanophytosomes. 
6. Testing of  in vitro anti cancer activity of extract and nanophytosome of leaves 
of momordica charantia against MDA-MBhuman breast cancer cell lines. 
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4.3. Plan of Work 
It is planned to carry out this work as outline below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Collection of Momordica Charantia 
leaves 
Preparation of aqueous extract of 
Momordica   Charantia  leaves 
(Decoction method) 
Concentrate the  Momordica Charantia 
leaves extract 
Preparation of aqueous extract of 
Momordica Charantia nanophytosomes 
Preliminary phytochemical 
investigation, HPTLC  fingerprint 
analysis 
Characterization of 
nanophytosomes (PARTICLE 
SIZE,ZETA POTENTIAL, FTIR, 
DSC, SEM, XRD, TEM ANALYSIS) 
Invitro Anticancer  activity against 
MDA-MB human breast cancer cell 
lines 
MTT assay, Flow cytometric 
analysis 
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                                        5. MATERIALS AND METHODS 
5.1.Materials  
Cholesterol were obtained from Loba Chem lab pvt ltd, Maharashtra. Phosphotidyl 
Choline is obtained from Lipoid pharma pvt ltd , Germany. Chloroform was obtained 
from Sisco Research lab, pvt ltd, Mumbai. All reagents and glass ware used are of 
analytical grade.  
5.2.Methodology 
5.2.1. Collection and Processing of Momordica Charantia Plant Material 
Momorica Charantia plants were collected locally from the village of Muhavur, 
Srivilliputhur (Virudhunagar Dist,Tamilnadu). The leaves were separated from the 
plant and the leaves were washed with water and then again washed with chloroform 
to remove soil particles and the leaves were spread and dried in the shade for 4 
days. 
5.2.2 Preparation of Aqueous Extract of Momordica Charantia 
The momordica charantia leaves were subjected to size reduction by trituration  by 
using mortar and pestle to make into fine powder. Weigh 10g of powder and it is 
dissolved in a 250ml  of boiling water. Then the mixture of powder and water is 
placed in water bath at 400c for 1 hour. Then it is filtered by using whatmann filter 
paper. Then the filtrate was concentrated on water bath at 400c for 2days.Then 
finally extract was collected and stored in desicator at room temperature. 
5.2.3. Preliminary Phytochemical Analysis [89] 
The aqueous extract of momorica charantia obtained was subjected to qualitative 
analysis to test the presence of various phytochemicals like alkaloids, flavonoids, 
steroids, phenols, proteins and amino acids, terpenoids,anthraquinones and 
quinones etc. 
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Procedure 
I. Test for Alkalaoids 
A. Mayer’s test 
A fraction of extract was treated with mayers test reagent(1.36 g of mercuric chloride 
and 5g of potassium iodide in 100ml water) and observed for the formation of cream 
coloured precipitate. 
B. Wagner’s test 
A fraction of extract was treated with wagner’s test reagent (1.27 g f iodide and 2g of 
potassium iodide in 100 water)  and observed for the formation of reddish brown 
coloured precipitate. 
C. Hager’s test 
A few ml of extract was treated with hager’s  test reagent(saturated aqueous solution 
of picric acid)  and observed for the formation of prominent yellow coloured 
precipitate. 
II. Test for Flavanoids 
A. NaoH test 
A small amount of extract was treated with aqueous NaoH and HCl, observed for the 
formation of yellow orange colour. 
B. H2SO4 test 
A fraction of extract was treated with concentrated H2SO4  and observed for the 
formation of orange colour. 
III. Test For Sterols 
A. Liebermann-Burchard test 
A fraction of extract was treated with  chloroform, acetic anhydride and drops of 
concentrated H2SO4 was added and observed for the formation of pink or red colour. 
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IV.Test for Phytosterols  
A. Salkowski test  
The fraction of extract was dissolved in few drops of acetic acid and three drops of 
acetic anhydride was added followed by few drops of concentrated sulfuric acid. 
Bluish green colour was formed shows the presence of phytosterol. 
V. Test for Terpenoids 
A. Liebermann-Burchard test 
A fraction of extract was treated with  chloroform, acetic unhydride and drops of 
concentrated H2SO4 was added and observed for the formation of greyish colour. 
VI. Test for Proteins and Amino Acids 
A. Ninhydrin test (aqueous) 
A fraction of extract was treated with aqueous ninhydrin and observed for the 
formation of blue  colour, indicating presence of amino acids or purple colour 
indicating the presence of protein. 
B. Ninhydrin test (acetone) 
Ninhydrin was dissolved in acetone,the extract was treated with  ninhydrin and 
observed for the formation of purple colour. 
C. Biuret test 
The extract was heated in distiiled water and filtered. The filtrate is treated with 
2%copper sulphate solution,to this added 95%ethanol and potassium hydroxide and 
observed the formation of pink colour.  
VII. Test for Anthraquinones 
A. Borntrager’s test 
About 50mg of powdered extract was heated with 10%ferric chloride solution and 
1ml concentrated HCl. The extract was cooled, filtered and the filtrate was shaken 
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with diethyl ether. The ether extract was further extracted with strong ammonia; pink 
or deep red colour of aqueous layer indicate the presence of anthraquinones. 
VIII. Test for Phenols 
A. Ferric chloride test 
A fraction of extract was treated with 5% ferric chloride  and observed for the 
formation of deep black or blue colour. 
B. Liebermann’s test 
The extract was heated with sodium nitrite, added H2SO4 solution diluted with water 
and excess of dilute NaoH was added and observed for the formation of deep red or 
green or blue colour. 
IX. Test for Tannins 
A. Ferric chloride test 
A small amount of extract was treated with ferric chloride solution and observed for 
the formation of bluish black colour. 
X. Test for saponins 
A. Foam test 
A small amount of extract was added with water and shaken well and observed for 
the formation of foams. 
5.2.4. HPTLC Fingerprint Analysis[90] 
HPTLC finger printing analysis of aqueous extract of momordica charantia 
leaves 
Preliminary phytochemical analysis for momordica charatia leaves extracts were 
carried out as per the protocol mentioned in Harbore,1998 (Paterson, 1999).  For 
HPTLC (silica gel G 60F254 TLC plates of E. Merck, layer thickness 0.2 mm) 
fingerprint analysis  was established for aqueous extracts  of momordica charantia 
leaves. HPTLC was performed on (10 cm X 10 cm) aluminum backed plates coated 
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with silica gel 60F254 (Merck, Mumbai, India). Standard solution of quercetin and 
test were applied to the plates as bands 8.0 mm wide, 30.0 mm apart, and 10.0 mm 
from the bottom edge of the same chromatographic plate by use of a Camag 
(Muttenz, Switzerland) Linomat V sample applicator equipped with a 100 µL 
Hamilton (USA) syringe. Ascending development to a distance of 80 mm was 
performed at room temperature (28±2oc ), with toluene: ethyl acetate: formic acid [(5: 
4: 1) (v/v/v)], as mobile phase, in a Camag glass twintrough chamber previously 
saturated with mobile phase vapour for 20 min. Quercetin of (100 µg/mL) was used 
as standard (Vijayalakshmi, Ravichandiran, Malarkodi, Nirmala, & Jayakumari, 
2012).  
5.2.5. Preparation of Nanophytosomes: Thin film hydration method 
Accurately weighed quantity of egg lecithin and cholesterol were  dissolved in 10 ml 
of chloroform in round bottom flask (RBF) and sonicated for 10 min using bath 
sonicator. Organic solvent removal is done by Rotary evaporator (45-50°C). After 
complete removal of solvent thin layer of phospholipids mixture was formed. This film 
was hydrated with Aqueous extract of momorica charantia leaves in rotary 
evaporator (37-40°C for 1 hour). After hydration, mixture of lipid and plant extract 
was sonicated for 40 minutes in presence of ice bath for  heat dissipation. Then 
prepared phytosomes were filled in amber colored bottle and stored in freezer (2-
8 0C) until used. The different phytosome complexes of momorica charantia  F1, F2, 
F3 & F4 containing molar ratio of 1:0.5:1, 2:1:1, 1:0.5:2 and 2:1:2 of Egg lecithin, 
Cholesterol and momorica charantia  were prepared as mentioned in ( Table 5) 
Composition of phytosome formulation of aqueous extract of momorica charantia 
leaves. 
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Table 1.5: Composition of phytosome formulation of aqueous extract of 
momorica    charantia leaves 
Phytosomes
Molar ratio 
(EL:CL:EX) 
chloroform
F1 1:0.5:1 10ml 
F2 2:1:1 10ml 
F3 1:0.5:2 10ml 
F4 2:1:2 10ml 
                             EL: Egg Lecithin; CL: Cholesterol; EX: Extract 
5.2.6. Characterization  of Nanophytosomes[91] 
5.2.6.1. Particle size 
Particle size of prepared nanophytosomes was analyzed by photon correlation 
spectroscopy using a Shimadzu particle size analyzer (SALD 2101, Japan). Diluted 
nanophytosomal suspension was placed into the sample dispersion unit while stirring 
at room temperature (in order to reduce the inter particle aggregation). All analyses 
has been performed in triplicate. 
 5.2.6.2. Zeta potential determination 
Surface charge of momorica charantia -loaded nanophytosomes was determined 
using a Malvern Zetasizer (Nano-ZS, UK). Samples were diluted (50 folds) using 
distilled water and then analysis was performed at 25 ºC and 149 watt. The average 
three zeta potential determination of the nanophytosomes was calculated.   
5.2.6.3. Fourier Transformer-Infra Red Spectroscopy (FTIR) analysis 
FT-IR  spectral data can be taken to determine the structure and chemical stability of 
pure drug in the presence of excipients, physical mixture of egg lecithin and 
cholesterol, physical mixtures and nanophytosomal formulation. were evaluated by 
FT-IR analysis. The spectroscopic evaluation of the formed complex can be 
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confirmed by FTIR simply by mparing the spectrum of the complex and the individual 
components and that of the mechanical mixtures. Samples were mixed with dry 
crystalline KBr in a ratio of 1:100 and pellets were prepared. The mixture was 
grounded or triturated into fine powder using an agate mortar before compressing 
into KBr disc. Each KBr disc was scanned at 4 mm/s at a resolution of 2. FTIR can 
also be considered as a valuable tool in confirming the stability of the phytosomal 
complex. FT-IR spectra were obtained using a FT-IR spectrometer . Spectral 
scanning can be done in the range between 4000-400 cm-1. 
5.2.6.4. Differential Scanning Calorimetry (DSC) analysis 
Thermodynamical techniques are applied for determining the thermal stress of 
medicinal compounds of the excipients as well as their interactions during the 
formulation process. The thermal analysis of the momordica charantia, physical 
mixture of egg lecithin and cholesterol, physical mixture of egg lecithin and 
cholesterol and extract of momorica charantia were placed in the aluminum crimp 
cell and heated at 100C/min from 0 to 4000C in the atmosphere of nitrogen (TA 
Instruments, USA, model DSC Q10 V24.4 Build 116). Peak transition onset 
temperatures were recorded by means of an analyzer. Momorica charantia leaves 
extract, phospholipon and phytosome were placed in the aluminum crimp cell and 
heated at 100C/min from 0 to 400 0C in the atmosphere of nitrogen (TA Instruments, 
USA, Model DSC Q10 V24.4 Build 116). Peak transition onset temperatures were 
recorded by means of an analyzer. 
5.2.6.5. Scanning Electron Microscopy (SEM) analysis 
Scanning electron microscopy has been used to determine particle size distribution 
and surface morphology of the complexes. Samples were studied using JEOL JSM-
6360 Scanning microscope (Japan).  Approximately 5 μL of the nanophytosomal 
suspension was transformed to a cover slip, which in turn was mounted on a 
specimen tab. The samples were allowed to dry at room temperature. Then the 
particle size of the formulation was viewed and photographed using Scanning 
Electron Microscope (Sigma, Carl Zeiss). The particles were coated with platinum by 
using vaccum evaporator and thus, the coated samples were viewed and 
photographed in JEOL JSM-6701F Field Emission SEM. Digital images of 
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phytosome complex of momorica charantia  were taken by random scanning of the 
stub at different magnifications. 
5.2.6.6. X-Ray Diffraction (XRD) analysis 
XRD is a unique method in determination of crystallinity of a compound and when 
properly interpreted, by comparison with drug XRD pattern before formulation., 
allows the identification of the drug crystalline changes. XRD was done on pure 
extract, physical mixtures of egg lecithin and cholesterol, physical mixtures and 
nanophytosome to see the crystallinity in the substance. Sample was scanned in the 
angular range of 50 - 800 in a PHILIPS XPert Pro X-Ray Diffractometer. Dried 
powder sample was kept in sample holder (20 mm × 15mm × 2mm) which was fitted 
into the instrument and X-ray was passed through the sample. 
5.2.6.7. Transmission Electron Microscopy (TEM) analysis 
Vesicles morphology of nanophytosome was observed visually with a JEOL JEM 
1400 (Japan) Transmission Electron Microscopy (TEM). A total volume of 10 ml 
sample was dispersed before the sample was analyzed. The mixture was then 
stirred and a drop of the sample was placed on the specimen. The 400 mesh grid 
was placed over the specimens and allowed to stand for 1 minute. Residual droplets 
on the grid were cleaned using a filter paper. A drop of 5 uranyl acetate was dropped 
over the grid and the rest of the excess solution was removed using a filter paper. 
The grid was left for 30 minutes and the films were then viewed on a transmission 
electron microscope and photographed. 
5.3. IN-VITRO STUDIES 
5.3.1. Cell Culture 
The MDA-MBcells were grown and maintained in a humified incubator at 37˚C under 
5% Co2 atmosphere in MEM medium (Minimal Essential Media) supplemented with 
TPVG & 10% Fetal calf serum and (100 units/ml penicillin).For experimental purpose 
cells were plated in 48 well plates (at a density of 1x104cells/ ml). After 25hrs 
incubation period , to allow cell attachment, the cells were treated with fresh medium 
containing different concentration of aqueous  extract and nanophytosomes of 
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leaves of Momordica Charantia ranging from 10-100 μg/ml, dissolved in DMSO and 
incubated for 48hrs and it is used for study of MTT assay[92].  
5.3.2. MTT Assay 
It is a sensitive, quantitative and reliable colorimetric assay that measure viability, 
proliferation and activation of cells. The assay is based on the capacity of the cellular 
mitochondrial dehydrogenase enzyme in living cells to reduce the yellow water-
soluble substrate 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide (MTT) 
into a dark blue/purple formazan product which is insoluble in water. The amount of 
formazan produced is directly proportional to the cell number in a range of cells 
lines.At the end of 48hrs incubation, the medium in each plate containing the 
aqueous extract of nanophytosomesof leaves of Momordica charantia was added 
with 200μl of MTT solution and incubated for another 4hrs.The supernatant was then 
removed & replaced with 500μl of DMSO to dissolve the resulting MTT formazan 
crystals followed by mixing & measuring the absorbance at 590nm[93].  
Cell viability % = OD of sample / OD of control ×100 
OD: Optical Density 
5.3.3. Flow Cytometric Analysis 
Harvest MDA-MBcells and aliquot up to 1 x 106 cells/100 μL into FACS tubes. Wash 
the cells 2 times by adding 2 mL of PBS (or HBSS), centrifuging at 300 x g for 5 
minutes, and then decanting the buffer from the pelleted cells. Resuspend cells in 
100 µL of Flow Cytometry Staining Buffer. To adjust flow cytometer settings for PI, 
add 5 - 10 µL of PI staining solution to a control tube of otherwise unstained cells. 
Mix gently and incubate for 1 minute in the dark. Determine PI fluorescence (using 
the FL-2 or FL-3 channel) with a FACScan™ instrument. Acquire data for unstained 
cells and single-color positive controls. Add 5 - 10 µL of PI staining solution to each 
sample just prior to analysis. Set the stop count on the viable cells from a dot-plot of 
forward scatter versus PI[94]. 
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6. RESULTS AND DISCUSSION 
 Phytochemical Investigation 
 The results of the phytochemical study were tabulated in Table6.1. The phytochemical  
screening of the aqueous extract of momordica charantia leaves revealed the presence 
of steroids, flavonoids, alkaloids, sterols, phytosterols, terpenoids, tannins, proteins and 
amino acid, phenols, saponins. Tannins were absent in aqueous extract of momordica 
charantia. 
Table6.1: Preliminary phytochemical screening of momordica charantia leaves extract. 
S.No. Test Results 
1. TEST FOR ALKALOIDS  
 A. Mayer’s test + 
 B. Wagner’s test + 
 C. Hager’s test + 
2. TEST FOR FLAVANOIDS  
 A. NaoH test + 
 B. H2SO4 + 
3. TEST FOR STEROLS  
 A. Liebermann-Burchard test + 
4. TEST FOR PHYTOSTEROLS  
 A.  Salkowski test + 
5. TEST FOR TERPENOIDS  
 A.  Liebermann-Burchard test + 
6. TEST FOR PROTEIN AND AMINO 
ACID 
 
 A. Ninhydrin(aqueous) + 
 B. Ninhydrin(acetone)s + 
 C. Biuret test + 
7. TEST FOR ANTHRAQUINONES  
 A.Borntrager’s test + 
8. TEST FOR PHENOLS  
 A.  Ferric chloride test + 
 B.  Liebermann test + 
9. TEST FOR TANNINS  
 A. Ferric chloride test - 
10. TEST FOR SAPONINS  
 A. Foam test + 
  
(+)indicatespositive reaction                                         (-)indicates negativereaction 
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 HPTLC finger printing analysis of aqueous extract of momordica charantia 
leaves 
 Preliminary phytochemical investigation divulges the presence of glycosides, 
phenolic compounds, flavonoids, proteins, amino acids and saponins in aqueous 
extracts of momordica charantia . Hence, momordica charantia leaves extract 
containing higher alttitude of phytoconstituents which may possibly  take part in 
reactions in effective reduction of  nanophytosomess . (Martinez-Perez et al., 2014) . 
However, HPTLC finger print analysis also confirms the presence of MCAE (Fig. 6.1) 
flavonoid which has influenced the conversion of nanophytosomes due to easily 
oxidizable conjugated hydroxyl groups in the molecule (Terenteva, Apyari, 
Dmitrienko, & Zolotov, 2015). 
                
Figure6.1. HPTLC finger printing analysis of aqueous extract of momordica charantia 
leaves 
 Characterization of MCAE nanophytosomes  
 Particle size 
Particle size plays an important role in the stability, availability and organoleptic 
properties of the solution and the particles with smaller size is desirable. Results of 
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particle size analysis indicated that nanophytosomes prepared with MCAE and PC 
possess the particle size in the average range of 584.1nm. Vesicle size tends to 
increase with increasing concentration of the complex. When the concentration of 
particles is too high, physical interaction either collision or electrostatic between 
vesicle is more pronoun. These interactions alter the movement of the particles and 
produce vesicles with a larger size. The high lipid composition in the formulation also 
increases the tendency for the formation of agglomerates, resulting in the bigger size 
of the vesicles. Polydispersity index is a measure of the heterogenecity of sizes of 
particles in a mixture momordica charantia nanophytosomes prepared show 
polydispersity index value of 0.4. 
 
Figure 6.2 particle size of aqueous extract momordica charantia nanophytosomes 
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Zeta Potential 
 The Zeta potential is the electric potential in the interface or particle surface and is 
used to predict the stability of colloidal systems. Colloids with high absolute Zeta 
potential values (normally above 30 mV), regardless of their positivity or negativity, 
are electrically stabilized and those with low Zeta potential values are not stable and 
tend to coagulate or flocculate. In general, higher Zeta potential values indicate a 
higher and longer-term stability of the particles. Several factors such as pH, ionic 
strength, type and concentration of the used biopolymers are effective on the Zeta 
potential of the particles. The surface charge analysis results (-23.8 mV) are shown 
in (Figure 6.1) and point to the high physical stability of MCAE nanophytosomes. 
 
Figure6.3 Zeta Potential Distribution 
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 Fourier Trasform-Infra Red Spectroscopy(FT-IR)Studies 
 Spectroscopic analysis was used in order to identify and diagnose of complex 
formation between PC and extract. In FTIR spectroscopy, functional groups and their 
numbers were identified from the frequency of radiation that absorbs infrared spectra 
which showed the main chemical groups in extract and PC as well as the formation 
of new interactions between them in the nanophytosomes preparation process. The 
FTIR spectroscopy of Momordica charantia leaf extract and excipients are shown in 
Figure 6.4, 6.5, 6.6. (Figure 6.4) shows that the characterstic O-H peak at 
3300.20cm-1, C≡N peak at 2357.01 cm-1, C≡C peak at 2169.92 cm-1, C=C peak at 
1988.61 cm-1, C=C peak at 1635.64 cm-1.(Figure 6.5) shows that the C-H peak at 
3020.53 cm-1, C=C peak at 1988.61 cm-1, C=O peak at 1734.01 cm-1, C-N peak at 
1215.15 cm-1,O-H peak at 927.76 cm-1, C-H peak at 744.52 cm-1, C-Br peak at 
667.37 cm-1.  (Figure 6.6) shows that the characterstic O-H peak at 3302.13 cm-1,  
C≡ N peak at 2360.87 cm-1, C≡C peak at 2167.99cm-1, C=C peak at 1990.54 cm-1, 
C=C peak at 1635.64 cm-1. Hence there is no apperence of new peaks and 
disapperence of existence peaks in the presence of excipients indicates the MCAE 
and excipients are more compatible. 
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Figure 6.4.  FT-IR studies of momordica charantia aqueous extrac.t  
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                        Figure. 6.5. FT-IR studies of phosphodityl-choline with cholesterol. 
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Figure.6.6. FT-IR studies of momordica charantia aqueous extract with excipients.  
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                                        Table 6.2. Interpretation of FT-IR studies 
 
S.No. Functional group Wavenumber(cm-1) 
Reference Extract Placebo Extraxt+placebo
1. O-H 
Stretch(carboxylic 
acid) 
 
3300-2500 
  
3300.20 
              
         _ 
      
3302.13 
2. CΞN 
stretch(nitriles) 
2260-2210 2357.01          _ 2360.87 
3. CΞN 
stretch(alkynes) 
2260-2100 2169.92          _  2169.99 
4. C=C 
stretch(alkenes) 
1900-2000 2013.68 1988.61 2021.40 
5. C=C 
stretch(alkenes) 
1900-2000 1988.61          _ 1990.54 
6. C=C 
stretch(alkenes)  
1900-2000 1955.82          _ 1959.68 
7. C=C 
stretch(alkenes) 
1640-1680 1635.64          _ 1635.64 
8. C-H 
stretch(aromatic) 
3100-3000          _ 3020.53        _ 
9. C-H 
stretch(alkenes) 
3100-3000          _ 2929.87        _ 
10. C=O 
stretch(aldehyde, 
saturated 
aliphatic) 
1720-1740          _ 1734.01         _ 
11. C-N 
stretch(aliphatic 
amines) 
1020-1250         _ 1215.15 1230.15 
12. C-N 
stretch(aliphatic 
amines) 
1020-1250         _ 1053.13 1072.15 
13. O-H 
bending(carboxylic 
acid) 
950-910         _ 927.76 928.17 
14. C-Br stretch(alkyl  
halides) 
690-515         _ 667.37         _ 
15. CΞN 
stretch(alkynes) 
2260-2100         _       _ 2223.92 
16. C=C 
stretch(alkenes) 
1900-2000         _       _ 2061.90 
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Differential Scanning Calorimetry(DSC) Studies 
 Differential scanning calorimetry studied were conducted the pure MCAE, 
cholesterol, phosphatidylcholine. The endothermic peak of MCAE was observed at 
117.7 ºC (Figure6.5) corresponding to its melting point. DSC thermogram of 
phosphotidyl choline and cholesterol also showed endothermic peaks at 159.4°C, 
respectively (Figure 6.6). DSC Thermogram of MCAE with excipients (Figure 6.7)  
showed  endothermic  peaks 132.460C. When compared the endothermic peak of 
extract (117.70C) with endothermic peak of extract placebo(132.460C) showed  that 
there is no wide variation between the endothermic peaks and the difference is with 
in (±200C). This slight variation in the endothermic peaks may be due to the physical 
interaction between extract and phenol group OH.  
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0.00
10.00
20.00
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Heat
File Name: FI.tad
Detector: DSC-60
Acquisition Date18/03/16
Acquisition Time10:53:29(+0530)
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Sample Weight: 3.000[mg]
Annotation:
Thermal Analysis Result
FI.tad DSC
 
                Figure. 6.7. DSC thermogram of momordica charantia aqueous extract. 
 RESULTS AND DISCUSSION 
Department of Pharmaceutics, AKCP Page 60 
 
100.00 200.00 300.00
Temp [C]
0.00
10.00
mW
DSC
File Name: FIII.tad
Detector: DSC-60
Acquisition Date18/03/16
Acquisition Time11:58:40(+0530)
Sample Name: FIII
Sample Weight: 3.000[mg]
Annotation:
Thermal Analysis Result
FIII.tad DSC
 
Figure.6.8. DSC thermogram of phosphotidyl choline and cholesterol. 
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                              Figure 6.9. DSC thermogram of MCAE with excipients. 
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 Scanning Electron Microscopy Studies 
 Scanning electron microscopy give important insight into the solid state properties 
and surface morphology of drug and drug complexes. SEM images(Figure 6.8) of 
prepared MCAE nanophytosomes ,respectively. These images showed spherical 
shaped MCAE nanophytosomes with a size of 100-500nm. 
        
Figure6.10. SEM images for aqueous extract of momordica charantia 
nanophytosomes  
IN VITRO ANTI-CANCER ACTIVITY OF MOMORDICA CHARANTIA PLANT 
EXTRACT AND NANOPHYTO SOMES  
MTT assay 
 In this study, the cytotoxicity of  aqueous extract of momordica charantia and    
nanophytosome were tested against MDA-MBhuman breast cancer cell lines. The 
anti-cancer property of extract and nanophytosomes was determined by MTT assay. 
The principle of this assay is based on the reduction of a soluble tetrazolium salt, by 
mitochondrial dehydrogenase activity of viable cells, into a soluble coloured 
formazan product that can be measured spectrophotometrically, after dissolution 
 RESULTS AND DISCUSSION 
Department of Pharmaceutics, AKCP Page 62 
 
with DMSO. This assay determines the integrity of mitochondria and reflects the 
anti-proliferative effect or cell death. The aqueous extract at 6.25, 12.5, 25, 50 and 
100μg/ml (Figure6.11). 
 
Figure6.10 MTT assay of momordica charantia nanophytosomes by MDA-MB breast 
cancer cell lines. 
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Table 6.3: Cell viability of MCAE Nanophytomes 
S.No. Concentration (μg/ml) Extract (μg/ml) 
Nanophytosomes 
(μg/ml) 
1 6.25 37.8 ± o.4 32 ± 0.2 
2 12.5 55    ± 0.2 41.6 ± o.4 
 
3 25 74.5 ± 0.2 70.5 ± 0.2 
4 50 84.8 ± o.4 82 ± 0.2 
 
5 100 90  ± 0.2 96 ± 0.1 
 
 
                     
Figure 6.12.Cell viability of MCAE Nanophytosomes 
 
                              
0
20
40
60
80
100
120
6.25 12.5 25 50 100
% 
ce
ll v
iab
lit
y
concentration μg/ml
MCAE
MCAENP
  
 
 
 
 
CONCLUSION 
 
 
 
 
 
 
 CONCLUSION 
Department of Pharmaceutics, AKCP Page 64 
 
                                            
                                                 7. CONCLUSION 
 
Nanophytosomes of aqueous extract of momordica charantia was successfully 
prepared and tested for breast cancer cell lines. The aqueous extract was evaluated 
phyto chemical screening followed by all characterization studies. Phytochemical 
screening study remaining that the extract consists of flavanoids. The 
characterization study showed that the phytosomes are having nano size, good 
stability properties with round to spherical shape with smooth surfaces. The MTT 
assay, extract and nanophytosomes showed that nanophytosomes are having more 
anti cancer activity. When compared with aqueous extract against MDA-MBbreast 
cancer cell lines. Hence, the prepared nanophytosomes showed excellent in vitro 
anti cancer activity. This work can be further extended to clinical trials.     
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